Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data

Ocugen, Inc. gene therapy outlook: key 2026 catalysts, Phase 2/3 eye-disease data, BLA plans to 2028, and risks. Click for ...

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense

Cardamyst FDA approval and launch for PSVT, solid cash, and big expansion upside. Click for more on MIST stock.
The Malaysian Reserve

New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder

CAPLYTA® nearly doubled the likelihood of remission at six weeks compared to placebo as an adjunctive therapy to an antidepressant based on pooled data ...

First on CNN: Noninvasive brain treatment for depression proves helpful

At Stanford, a treatment that aims magnetic pulses at the brain is showing results for people with treatment-resistant depression. It’s called SAINT, and here’s how it works.

What causes extreme morning sickness? What we know, don't know and suspect about hyperemesis gravidarum

Until about five years ago, scientists believed the pregnancy hormone, human chorionic gonadotropin (hCG), was the culprit.